Aligos Therapeutics, Inc. Operating Lease, Impairment Loss
Aligos Therapeutics, Inc. (ALGS) reported Operating Lease, Impairment Loss of $724.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseImpairmentLoss · last filed 2025-03-10
- Aligos Therapeutics, Inc. operating lease, impairment loss for the quarter ending 2023-12-31 was $0.00.
- Aligos Therapeutics, Inc. operating lease, impairment loss for the quarter ending 2023-09-30 was $0.00.
- Aligos Therapeutics, Inc. operating lease, impairment loss for the quarter ending 2023-06-30 was $700.00K.
- Aligos Therapeutics, Inc. operating lease, impairment loss for fiscal 2023 was $724.00K.
- Aligos Therapeutics, Inc. operating lease, impairment loss for fiscal 2022 was $0.00.
| Period end | Operating Lease, Impairment Loss 3 month | Operating Lease, Impairment Loss 6 month | Operating Lease, Impairment Loss 9 month | Operating Lease, Impairment Loss 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $0.00 derived: sum of 2 quarters · filed 2025-03-10 | $700.00K derived: sum of 3 quarters · filed 2025-03-10 | $724.00K 10-K · filed 2025-03-10 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-02 | $700.00K derived: sum of 2 quarters · filed 2023-11-02 | $724.00K 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $700.00K 10-Q · filed 2023-11-02 | $724.00K 10-Q · filed 2024-08-06 | ||
| 2022-12-31 | $0.00 10-K · filed 2024-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |